Abstract

<div>Abstract<p>Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC (<i>n</i> = 164) had distinctive molecular features when compared with NC4 (<i>n</i> = 102). These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed <i>PTEN</i> and <i>MAP3K7</i> losses and gains at 3q; (ii) increased <i>SPOP</i><sup>mut</sup> and <i>ATM<sup>mut</sup></i>; (iii) enrichment for <i>mTORC1</i> and <i>MYC</i> pathways by gene expression; and (iv) increased methylation of selected genes. In addition, when compared with the metastatic prostate cancer, ICC clustered more closely to metastatic prostate cancer than NC4. Validation in clinical cohorts and genomically annotated murine models confirmed the association with <i>SPOP<sup>mut</sup></i> (<i>n</i> = 38) and <i>PTEN<sup>loss</sup></i> (<i>n</i> = 818). The association of ICC with lethal disease was evaluated in the Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS) prospective prostate cancer cohorts (median follow-up, 13.4 years; <i>n</i> = 818). Patients with ICC were more likely to develop lethal cancer [HR, 1.62; 95% confidence interval (CI), 1.05–2.49], independent from Gleason score (GS).</p>Implications:<p>ICC has a distinct molecular phenotype that resembles metastatic prostate cancer and is associated with progression to lethal disease.</p></div>

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.